S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:CLLS

Cellectis Stock Forecast, Price & News

$8.24
-0.37 (-4.30%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.00
$8.67
50-Day Range
$8.24
$13.81
52-Week Range
$8.00
$34.71
Volume
264,201 shs
Average Volume
193,614 shs
Market Capitalization
$374.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.21
30 days | 90 days | 365 days | Advanced Chart
Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter.


Cellectis logo

About Cellectis

Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. It offers Gene editing and Immuno-oncology. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Headlines

Cellectis (NASDAQ:CLLS) Coverage Initiated at JMP Securities
November 30, 2021 |  americanbankingnews.com
Cellectis S.A. (NASDAQ:CLLS) Short Interest Down 38.0% in October
November 18, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLLS
Employees
340
Year Founded
N/A

Sales & Book Value

Annual Sales
$82.46 million
Book Value
$5.76 per share

Profitability

Net Income
$-81.07 million
Net Margins
-188.02%
Pretax Margin
-205.18%

Debt

Price-To-Earnings

Miscellaneous

Free Float
38,013,000
Market Cap
$374.67 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/04/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/03/2022

MarketRank

Overall MarketRank

1.93 out of 5 stars

Medical Sector

709th out of 1,390 stocks

Biological Products, Except Diagnostic Industry

111th out of 202 stocks

Analyst Opinion: 3.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Cellectis (NASDAQ:CLLS) Frequently Asked Questions

Is Cellectis a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cellectis stock.
View analyst ratings for Cellectis
or view top-rated stocks.

How has Cellectis' stock been impacted by Coronavirus (COVID-19)?

Cellectis' stock was trading at $11.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLLS shares have decreased by 27.9% and is now trading at $8.24.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Cellectis?

Cellectis saw a decrease in short interest in October. As of October 29th, there was short interest totaling 597,800 shares, a decrease of 38.0% from the October 14th total of 964,500 shares. Based on an average trading volume of 201,600 shares, the short-interest ratio is presently 3.0 days. Currently, 1.3% of the company's stock are sold short.
View Cellectis' Short Interest
.

When is Cellectis' next earnings date?

Cellectis is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Cellectis
.

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) released its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($0.82) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.82). Cellectis had a negative trailing twelve-month return on equity of 44.64% and a negative net margin of 188.02%. During the same period in the prior year, the company earned ($0.71) earnings per share.
View Cellectis' earnings history
.

What price target have analysts set for CLLS?

6 Wall Street analysts have issued twelve-month price objectives for Cellectis' stock. Their forecasts range from $10.00 to $33.00. On average, they anticipate Cellectis' stock price to reach $23.25 in the next twelve months. This suggests a possible upside of 182.2% from the stock's current price.
View analysts' price targets for Cellectis
or view top-rated stocks among Wall Street analysts.

Who are Cellectis' key executives?

Cellectis' management team includes the following people:
  • André Choulika, Chief Executive Officer & Director
  • Eric Dutang, Chief Financial Officer
  • Philippe Duchateau, Chief Scientific Officer
  • Francisco J. Esteva, Vice President-Clinical Development
  • Carrie Brownstein, Chief Medical Officer

What is André Choulika's approval rating as Cellectis' CEO?

4 employees have rated Cellectis CEO André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among Cellectis' employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

When did Cellectis IPO?

(CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Who are Cellectis' major shareholders?

Cellectis' stock is owned by a variety of retail and institutional investors. Top institutional investors include Principal Financial Group Inc. (2.73%), Baillie Gifford & Co. (2.37%), Sumitomo Mitsui Trust Holdings Inc. (1.53%), Nikko Asset Management Americas Inc. (1.53%), BlackRock Inc. (0.69%) and Exchange Traded Concepts LLC (0.52%).

Which major investors are selling Cellectis stock?

CLLS stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Principal Financial Group Inc., Barclays PLC, Advisor Group Holdings Inc., Citadel Advisors LLC, Citigroup Inc., and Henry James International Management Inc..

Which major investors are buying Cellectis stock?

CLLS stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Millennium Management LLC, Baillie Gifford & Co., KBC Group NV, BlackRock Inc., Exchange Traded Concepts LLC, Morgan Stanley, and Royal Bank of Canada.

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $8.24.

How much money does Cellectis make?

Cellectis has a market capitalization of $374.67 million and generates $82.46 million in revenue each year. The biotechnology company earns $-81.07 million in net income (profit) each year or ($2.93) on an earnings per share basis.

How many employees does Cellectis have?

Cellectis employs 340 workers across the globe.

What is Cellectis' official website?

The official website for Cellectis is www.cellectis.com.

Where are Cellectis' headquarters?

Cellectis is headquartered at 8 RUE DE LA CROIX JARRY, PARIS I0, 75013.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at (318) 169-1600, via email at [email protected], or via fax at 33-1-81-69-16-06.


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.